Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$44.82 USD

44.82
11,316,753

-1.03 (-2.25%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $44.83 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Zacks Equity Research

Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214

by Zacks Equity Research

Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.

    Zacks Equity Research

    Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses

    by Zacks Equity Research

    Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.

      Zacks Equity Research

      Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review

      by Zacks Equity Research

      Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.

        Zacks Equity Research

        Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag

        by Zacks Equity Research

        Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.

          Arpita Dutt headshot

          Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure

          by Arpita Dutt

          This week, focus was on earnings announcements from companies like Mylan (MYL), Perrigo and Endo.

            Zacks Equity Research

            AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

            by Zacks Equity Research

            AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

              Zacks Equity Research

              Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up

              by Zacks Equity Research

              Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q2 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

                Zacks Equity Research

                Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View

                by Zacks Equity Research

                Horizon Pharma plc (HZNP) topped both earnings and sales estimate in second-quarter 2017 and raised its sales guidance for 2017.

                  Sweta Killa headshot

                  Q2 Earnings Fail to Impress Pharma ETF

                  by Sweta Killa

                  The string of earnings beat failed to boost pharma ETFs.

                    Zacks Equity Research

                    Infinity (INFI) Q2 Loss Wider than Expected, View Intact

                    by Zacks Equity Research

                    Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.

                      Arpita Dutt headshot

                      Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals

                      by Arpita Dutt

                      Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.

                        Zacks Equity Research

                        Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales

                        by Zacks Equity Research

                        Exelixis' (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.

                          Zacks Equity Research

                          Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top

                          by Zacks Equity Research

                          Aduro (ADRO) incurs loss in Q2 but revenues beat estimates. However, the same declines year over year, courtesy a milestone payment from the year-ago quarter.

                            Zacks Equity Research

                            Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses

                            by Zacks Equity Research

                            Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.

                              Zacks Equity Research

                              The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts

                              by Zacks Equity Research

                              The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts

                                Zacks Equity Research

                                Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong

                                by Zacks Equity Research

                                Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.

                                  Zacks Equity Research

                                  What's in the Cards for Celldex (CLDX) this Earnings Season?

                                  by Zacks Equity Research

                                  With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

                                    Arpita Dutt headshot

                                    Key FDA Events to Watch Out for in Aug 2017

                                    by Arpita Dutt

                                    Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More

                                      by Arpita Dutt

                                      Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.

                                        Zacks Equity Research

                                        Seattle Genetics (SGEN) Q2 Loss Narrower than Expected

                                        by Zacks Equity Research

                                        Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.

                                          Zacks Equity Research

                                          Roche's (RHHBY) Sales Grow Y/Y in 1H17 on New Drug Launches

                                          by Zacks Equity Research

                                          Roche Holdings (RHHBY) delivered an impressive performance in 1H17 driven by new drug launches.

                                            Zacks Equity Research

                                            Company News For July 28, 2017

                                            by Zacks Equity Research

                                            Companies In The News Are: PG,MA,BMY,BUD

                                              Zacks Equity Research

                                              Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View

                                              by Zacks Equity Research

                                              Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates.

                                                Zacks Equity Research

                                                Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up

                                                by Zacks Equity Research

                                                Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.

                                                  Indrajit Bandyopadhyay headshot

                                                  Bristol-Myers (BMY) Q2 Earnings Beats Estimates

                                                  by Indrajit Bandyopadhyay

                                                  Bristol-Myers (BMY) reports second-quarter results beating both earnings and sales estimates.